Lineage Cell Therapeutics Inc (AMEX:LCTX) price on Wednesday, February 05, rose 7.59% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.71.
A look at the stock’s price movement, the close in the last trading session was $0.66, moving within a range at $0.6555 and $0.71. The beta value (5-Year monthly) was 1.282. Turning to its 52-week performance, $1.61 and $0.48 were the 52-week high and 52-week low respectively. Overall, LCTX moved 20.32% over the past month.
Lineage Cell Therapeutics Inc’s market cap currently stands at around $156.49 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 1.62M for the company’s revenue for the quarter, with a low and high estimate of 840k and 3.78M respectively. The average forecast suggests down to a -23.46% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 8.25M, representing a -7.73% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LCTX is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
LCTX’s current price about 15.97% and 24.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.11, while 7-day volatility ratio is 12.87% and 9.60% in the 30-day chart. Further, Lineage Cell Therapeutics Inc (LCTX) has a beta value of 1.26, and an average true range (ATR) of 0.06.
If we refocus on Lineage Cell Therapeutics Inc (AMEX:LCTX), historical trading data shows that trading volumes averaged 1.76 over the past 10 days and 2.65 million over the past 3 months. The company’s latest data on shares outstanding shows there are 220.42 million shares.
The 0.43% of Lineage Cell Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 47.62% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 15.94 million on 2024-10-31, giving us a short ratio of 35.21. The data shows that as of 2024-10-31 short interest in Lineage Cell Therapeutics Inc (LCTX) stood at 1089.0 of shares outstanding, with shares short rising to 15.22 million registered in 2024-09-30. Current price change has pushed the stock 41.29% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LCTX stock continues to rise going into the next quarter.
